Hypocretin in cerebrospinal fluid is positively correlated with Tau and pTau

Neuroscience Letters

Volumn 561, Issue , 2014, Pages 41-45

  Deuschle, Michael ^a   Schilling, Claudia ^a   Leweke, F Markus ^a   Enning, Frank ^a   Pollmächer, Thomas ^b,c   Esselmann, Hermann ^d   Wiltfang, Jens ^d,f   Frölich, Lutz ^a   Heuser, Isabella ^a,e  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^c KLINIKUM INGOLSTADT   (Germany)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

A ; Alzheimer's disease; Depression; Hypocretin; Orexin; Tau protein

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; CITALOPRAM; FLUOXETINE; HALOPERIDOL; LITHIUM; MELPERONE; MIRTAZAPINE; OLANZAPINE; OREXIN; OREXIN A; PHOSPHORYLATED TAU PROTEIN; PREGABALIN; REBOXETINE; RISPERIDONE; RIVASTIGMINE; SEROTONIN UPTAKE INHIBITOR; TAU PROTEIN; UNCLASSIFIED DRUG; VENLAFAXINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN METABOLISM; SLEEP WAKING CYCLE;

ALZHEIMER'S DISEASE; AΒ; DEPRESSION; HYPOCRETIN; OREXIN; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NEUROPEPTIDES; PEPTIDE FRAGMENTS; PHOSPHORYLATION; TAU PROTEINS;

EID: 84891912948     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.12.036     Document Type: Article

References (29)

1. Baumann C.R., Hersberger M., Bassetti C.L. Hypocretin-1 (orexin A) levels are normal in Huntington's disease. J. Neurol. 2006, 253:1232-1233.
2. Behn C.G.D., Kopell N., Brown E.N., Mochizuki T., Scammell T.E. Delayed orexin signaling consolidates wakefulness and sleep: physiology and modeling. J. Neurophysiol. 2008, 99:3090-3103.
3. Cross D.A.E., Alessi D.R., Cohen P., Andjelkovich M., Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin-mediated by protein kinase-B. Nature 1995, 378:785-789.
4. Dalal M.A., Schuld A., Pollmächer T. Lower CSF orexin A (hypocretin-1) levels in patients with schizophrenia treated with haloperidol compared to unmedicated subjects. Mol. Psychiatry 2003, 8:836-837.
5. Dubois B., Feldman H.H., Jacova C., Cummings J.L., Dekosky S.T., Barberger-Gateau P., Delacourte A., Frisoni G., Fox N.C., Galasko D., Gauthier S., Hampel H., Jicha G.A., Meguro K., O'Brien J., Pasquier F., Robert F., Rossor M., Salloway S., Sarazin M., de Souza L.C., Stern Y., Visser P.J., Scheltens P. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2009, 9:1118-1127.
6. Espana R.A., Reis K.M., Valentino R.J., Berridge C.W. Organization of hypocretin/orexin efferents to locus coeruleus and basal forebrain arousal-related structures. J. Comp. Neurol. 2005, 481:160-178.
7. Friedman L.F., Zeitzer J.M., Lin L., Hoff D., Mignot E., Peskind E.R., Yesavage J.A. In Alzheimer disease, increased wake fragmentation found in those with lower hypocretin-1. Neurology 2007, 68:793-794.
8. Fronczek R., van Geest S., Frölich M., Overeem S., Roelandse F.W., Lammers G.J., Swaab D.F. Hypocretin (orexin) loss in Alzheimer's disease. Neurobiol. Aging 2012, 33:1642-1650.
9. Harada S., Fujita-Hamabe W., Tokuyama S. Effect of orexin-A on post-ischemic glucose intolerance and neuronal damage. J. Pharmacol. Sci. 2011, 115:155-163.
10. Harper D.G., Stopa E.G., McKee A.C., Satlin A., Harlan P.C., Goldstein R., Volicer L. Differential circadian rhythm disturbances in men with Alzheimer's disease and frontotemporal degeneration. Arch. Gen. Psychiatry 2001, 58:353-360.
11. Hernandez F., Gomez de Barreda E., Fuster-Matanzo A., Lucas J.J., Avila J. GSK3: a possible link between beta amyloid peptide and tau protein. Exp. Neurol. 2010, 223:322-325.
12. Hulstaert F., Blennow K., Ivanoiu A., Schoonderwaldt H.C., Riemenschneider M., De Deyn P.P., Bancher C., Cras P., Wiltfang J., Mehta P.D., Iqbal K., Pottel H., Vanmechelen E., Vanderstichele H. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 1999, 52:1555-1562.
13. Jyoti A., Plano A., Riedel G., Platt B. EEG, activity and sleep architecture in a transgenic Aβ PPswePSEN1(A246E) Alzheimer's disease mouse. J. Alzheimers Dis. 2010, 22:873-887.
14. Kang J.E., Lim M.M., Bateman R.J., Lee J.J., Smyth L.P., Cirrito J.R., Fujiki N., Nishino S., Holtzman D.M. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 2009, 326:1005-1007.
15. McCurry S.M., Logsdon R.G., Teri L., Gibbons L.E., Kukull W.A., Bowen J.D., McCormick W.C., Larson E.B. Characteristics of sleep disturbances in community-dwelling patients Alzheimer's disease patients. J. Geriatr. Psychiatry Neurol. 1999, 12:53-59.
16. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34(7):939-944.
17. Moe K.E., Vitiello M.V., Larsen L.H., Prinz P.N. Sleep-wake patterns in Alzheimer's disease - relationships with cognition and function. J. Sleep Res. 1995, 4:15-20.
18. Pace-Schott E.F., Hobson J.A. The neurobiology of sleep: genetics, cellular physiology and subcortical networks. Nature Rev. Neurosci. 2002, 3:591-605.
19. Rouet-Benzineb P., Rouyer-Fessard C., Jarry A., Avondo V., Pousset C., Yanagisawa M., Laboisse C., Laburthe M., Voisin C. Orexins acting at native OX1 receptor in colon cancer and neuroblastoma cells or at recombinant OX1 receptors suppress cell growth by inducing apoptosis. J. Biol. Chem. 2004, 279:45875-45876.
20. Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nature Rev. Neurosci. 2007, 8:171-181.
21. Schmidt F.M., Kratzsch J., Gertz H.-J., Tittmann M., Jahn I., Pietsch U.-C., Kaisers U.X., Thiery J., Hegerl U., Schönknecht P. Cerebrospinal fluid melanin-concentrating hormone (MCH) and hypocretin-1 (HCRT-1, orexin-A) in Alzheimer's disease. PLoS ONE 2013, 8:e63136.
22. Schmidt F.M., Arendt E., Steinmetzer A., Bruegel M., Kratzsch J., Strauß M., Baum P., Hegerl U., Schönknecht P. CSF-hypocretin-1 levels in patients with major depressive disorder compared to healthy controls. Psychiatry Res. 2011, 190:240-243.
23. Tsuneki H., Murata S., Anzawa Y., Soeda Y., Tokai E., Wada T., Kimura I., Yanagisawa M., Sakurai T., Sasaoka T. Age-related insulin resistance in hypothalamus and peripheral tissues of orexin knockout mice. Diabetologia 2008, 51:657-667.
24. Tsuno N., Besset A., Ritchie K. Sleep and depression. J. Clin. Psychiatry 2005, 66:1254-1269.
25. Vanmechelen E., Vanderstichele H., Davidsson P., van Kerschaver E., van der Perre B., Sjögren M., Andreasen N., Blennow K. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci. Lett. 2000, 285:49-52.
26. Van Someren E.J.W., Hagebeuk E.E.O., Lijzenga C., Scheltens P., deRooij S.E.A., Jonker G., Pot A.M., Mirmiran M., Swaab D.F. Circadian rest-activity rhythms in Alzheimer's disease. Biol. Psychiatry 1996, 40:259-270.
27. Vitiello M.V., Bliwise D.L., Prinz P.N. Sleep in Alzheimer's disease and the sundown syndrome. Neurology 1992, 42(Suppl. 6):83-94.
28. Wennström M., Londos E., Minthon L., Nielsen H.M. Altered CSF orexin and α-synuclein in dementia patients. J. Alzheimers Dis. 2012, 29:125-132.
29. Yi C.X., Serlie M.J., Ackermans M.T., Foppen E., Buijs R.M., Sauerwein H.P., Fliers E., Kalsbeck A. A major role for pernifornical orexin neurons in the control of glucose metabolism in rats. Diabetes 2009, 58:1998-2005.